PCVX: Vaxcyte, Inc. Stock

SIC 2836 – Biological Products, Except Diagnostic Substances (Biotech)

Valuation
Market Cap ($M) 4,017.36
Enterprise Value ($M) 3,629.48
Book Value ($M) 3,305.82
Book Value / Share 25.67
Price / Book 1.22
NCAV ($M) 1,582.49
NCAV / Share 12.29
Price / NCAV 2.54

Profitability (mra)
Return on Invested Capital (ROIC) -0.14
Return on Assets (ROA) -0.22
Return on Equity (ROE) -0.23

Liquidity (mrq)
Quick Ratio 12.75
Current Ratio 12.75

Balance Sheet (mrq) ($M)
Current Assets 1,787.98
Assets 3,511.32
Liabilities 205.50
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income -569.55
Net Income -463.93

Cash Flow Statement (mra) ($M)
Cash From Operations -452.63
Cash from Investing -2,005.67
Cash from Financing 2,448.51

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)
Change
(%)
02-14 13G/A Janus Henderson Group Plc 8.50 -3.17
02-12 13G/A Fmr Llc 10.50 -17.10
11-14 13G/A Ra Capital Management, L.p. 9.99 30.61

Top 13F Investors Shares
(1000)
Change
(%)
Value
($1000)
Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2025-02-25 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K
2024-11-05 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q
2024-08-06 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q
2024-05-08 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2025-04-14 405,762 1,785,670 22.72
2025-04-11 589,849 3,678,725 16.03
2025-04-10 401,072 2,618,287 15.32
2025-04-09 646,579 5,084,325 12.72

(click for more detail)

Similar Companies
OVID – Ovid Therapeutics Inc. PBYI – Puma Biotechnology, Inc.
PCRX – Pacira BioSciences, Inc. PEPG – PepGen Inc.
PGEN – Precigen, Inc.


Financial data and stock pages provided by
Fintel.io